Catching DDMAC's Eye: Leaving Out Risk Information Proves Risky Practice For ISTA
This article was originally published in The Pink Sheet Daily
Executive Summary
ISTA receives a second warning letter from FDA in just over a year for promotional material that omits risk information for its lead ophthalmic product.